|Bid||311.10 x 100|
|Ask||319.90 x 100|
|Day's Range||314.44 - 317.96|
|52 Week Range||244.28 - 330.00|
|PE Ratio (TTM)||20.67|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Tesla (TSLA) is teaming up with AMD (AMD) to develop its own AI chip for self-driving cars, according to a report by CNBC. Jefferies analyst Mark Lipacis wrote it’s a “critical win” for AMD. On the other hand, Nvidia (NVDA) shares are falling on the news, since a partnership with AMD would make Tesla less reliant on the company.
These drug juggernauts could bolster the entire biotechnology sector as we head toward year-end.
Just as one analyst goes bullish on Biogen (BIIB), another has moved to the sidelines. Earlier today, Raymond James analyst Laura Chico cut her rating on the stock by two notches, from a Strong Buy to a Market Perform (skipping over Outperform entirely) and lowered her price target from $329 a share to $319 a share. Chico sees continued headwinds for Biogen’s all-important multiple sclerosis drug franchise as a rival drug from Roche (RHHBY) gains market share.